Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 1
2021 1
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Large B cell lymphoma microenvironment archetype profiles.
Li X, Singhal K, Deng Q, Chihara D, Russler-Germain D, Harkins RA, Henderson J, Arita K, Kizhakeyil A, Sun R, Lakra P, Hussein U, Foltz JA, Wilson A, Schmidt E, Nizamuddin I, Dinh T, Kesaraju A, Hamilton MP, Allen C, Gandhi MK, Tobin J, Jiang A, Hilton L, Scott DW, Vega F, Flowers CR, Westin JR, Griffith OL, Fehniger TA, Griffith M, Green MR. Li X, et al. Among authors: tobin j. Cancer Cell. 2025 Jul 14;43(7):1347-1364.e13. doi: 10.1016/j.ccell.2025.06.002. Epub 2025 Jun 18. Cancer Cell. 2025. PMID: 40920660 Free article.
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.
MacManus MP, Seymour JF, Tsang H, Fisher R, Keane C, Sabdia MB, Law SC, Gunawardana J, Nath K, Kazakoff SH, Marques-Piubelli ML, Duenas DE, Green MR, Roos D, O'Brien P, McCann A, Tsang R, Davis S, Christie D, Cheah C, Amanuel B, Cochrane T, Butler J, Johnston A, Shanavas M, Li L, Vajdic C, Kridel R, Shelton V, Hershenfield S, Baetz T, Lebrun D, Johnson N, Brodtkorb M, Ludvigsen M, d'Amore F, Thompson ER, Blombery P, Gandhi MK, Tobin JWD. MacManus MP, et al. Among authors: tobin jwd. EBioMedicine. 2024 Dec;110:105468. doi: 10.1016/j.ebiom.2024.105468. Epub 2024 Dec 3. EBioMedicine. 2024. PMID: 39631145 Free PMC article. Clinical Trial.
PFS of IFRT + R-CVP-treated patients compared with all other treatments lacking rituximab (IFRT alone plus IFRT + CVP) was superior (HR = 0.36, 95% CI = 0.13-0.82, p = 0.013). Amongst PET-staged patients, PFS differences between IFRT + R-CVP vs. IFRT were maintained …
PFS of IFRT + R-CVP-treated patients compared with all other treatments lacking rituximab (IFRT alone plus IFRT + CVP) was superior ( …
Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance.
Boyle S, Tobin JWD, Perram J, Hamad N, Gullapalli V, Barraclough A, Singaraveloo L, Han MH, Blennerhassett R, Nelson N, Johnston AM, Talaulikar D, Karpe K, Bhattacharyya A, Cheah CY, Subramoniapillai E, Bokhari W, Lee C, Hawkes EA, Jabbour A, Strasser SI, Chadban SJ, Brown C, Mollee P, Hapgood G. Boyle S, et al. Among authors: tobin jwd. Hemasphere. 2021 Oct 11;5(11):e648. doi: 10.1097/HS9.0000000000000648. eCollection 2021 Nov. Hemasphere. 2021. PMID: 34651103 Free PMC article.
RIS occurred in 88% of patients. For patients initially treated with R-monotherapy, 45% achieved complete remission, rising to 71% with the addition of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) for those not in complete remission. …
RIS occurred in 88% of patients. For patients initially treated with R-monotherapy, 45% achieved complete remission, rising to 71% wi …
An Economic Evaluation of the TROG 99.03 Trial: Systemic Therapy After Radiotherapy in Early-Stage Follicular Lymphoma.
Erku D, Tobin JWD, Seymour JF, MacManus M, Scuffham P, Hapgood G. Erku D, et al. Among authors: tobin jwd. EJHaem. 2025 Feb 12;6(1):e70002. doi: 10.1002/jha2.70002. eCollection 2025 Feb. EJHaem. 2025. PMID: 39944796 Free PMC article.
AIM: We performed a cost-effectiveness analysis of RT (reference), RT+CVP, and RT+R-CVP from the TROG 99.03 trial. METHODS: We constructed a Markov model (15-year horizon) to compare treatments: RT (reference), RT+CVP and RT+R-CVP from the 150 patients in the TROG 9 …
AIM: We performed a cost-effectiveness analysis of RT (reference), RT+CVP, and RT+R-CVP from the TROG 99.03 trial. METHODS: We constr …
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.
Tobin JWD, Rule G, Colvin K, Calvente L, Hodgson D, Bell S, Dunduru C, Gallo J, Tsang ES, Tan X, Wong J, Pearce J, Campbell R, Tneh S, Shorten S, Ng M, Cochrane T, Tam CS, Abro E, Hawkes E, Hodges G, Kansara R, Talaulikar D, Gilbertson M, Johnston AM, Savage KJ, Villa D, Morris K, Ratnasingam S, Janowski W, Kridel R, Cheah CY, MacManus M, Matigian N, Mollee P, Gandhi MK, Hapgood G. Tobin JWD, et al. Blood Adv. 2019 Oct 8;3(19):2804-2811. doi: 10.1182/bloodadvances.2019000458. Blood Adv. 2019. PMID: 31570492 Free PMC article.
A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival.
Keane C, Tobin J, Talaulikar D, Green M, Crooks P, Jain S, Gandhi M. Keane C, et al. Among authors: tobin j. Oncotarget. 2018 May 4;9(34):23620-23627. doi: 10.18632/oncotarget.25306. eCollection 2018 May 4. Oncotarget. 2018. PMID: 29805761 Free PMC article.
EXPERIMENTAL DESIGN: A population based cohort of 210 patients (median age: 64, range 18-90 years) with median follow up 3.8 years was analysed. All patients were treated with R-CHOP, and no immunosuppression related cases were included. Tissue for nanoString gene expressi …
EXPERIMENTAL DESIGN: A population based cohort of 210 patients (median age: 64, range 18-90 years) with median follow up 3.8 years was analy …
Genetic aberrations of NLRC5 are associated with downregulated MHC-I antigen presentation and impaired T-cell immunity in follicular lymphoma.
Gunawardana J, Lee JN, Bednarska K, Murigneux V, de Long LM, Sabdia MB, Birch S, Tobin JWD, Gandhi MK. Gunawardana J, et al. Among authors: tobin jwd. EJHaem. 2020 Oct 14;1(2):517-526. doi: 10.1002/jha2.116. eCollection 2020 Nov. EJHaem. 2020. PMID: 35845006 Free PMC article.

Consistent with a pivotal role in the activation of CD8(+) T-cells, both CD8 and CD137 strongly correlated with NLRC5 expression (both r > 0.7; P < .0001). Further studies are required to determine whether patients with aberrant NLRC5 have a diminished response to im

…
Consistent with a pivotal role in the activation of CD8(+) T-cells, both CD8 and CD137 strongly correlated with NLRC5 expression (both r …